HANSOH PHARMA (03692): The application for marketing authorization of injectable HS-20093 for the treatment of small cell lung cancer has been accepted by the National Medical Products Administration.

16:32 02/09/2026

Hansen Pharmaceutical (03692) announced that on September 2, 2026, the groups innovative drug, injectable HS-20093, has had its marketing authorization application accepted by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with small cell lung cancer (SCLC) who have failed prior platinum-based therapies. Injectable HS-20093 is an antibody-drug conjugate (ADC) targeting B7-H3 independently developed by the group.

HANSOH PHARMA (03692) announced that on September 2, 2026, the application for marketing authorization of the innovative drug HS-20093 for injection was accepted by the National Medical Products Administration (NMPA) of China. This drug is intended for the treatment of adult patients with small cell lung cancer (SCLC) who have previously failed platinum-based therapies. HS-20093 for injection is an antibody-drug conjugate (ADC) targeting B7-H3 independently developed by the group.

SIMCERE PHARMA (02096) invested HKD 10.7033 million to repurchase 929,000 shares, demonstrating the company's confidence in its long-term development.

CLOUDBREAK-B (02592) will be suspended from trading starting the morning of September 10.

INSILICO (03696): The company's leading AI-driven candidate innovative drug Rentosertib has completed the enrollment of its first patient in a Phase III clinical trial for idiopathic pulmonary fibrosis.

SIMCERE PHARMA (02096) invested HKD 10.7033 million to repurchase 929,000 shares, demonstrating the company's confidence in its long-term development.

CLOUDBREAK-B (02592) will be suspended from trading starting the morning of September 10.